Phaseline

Targets › P2RX3

P2RX3 (P2X purinoceptor 3): drug programs, companies and trials

2 programs from 2 companies in 3 trials: 2 Phase 3, 1 Phase 2; Respiratory, Gastroenterology, Other; next expected readout Mar 2027.

Extracellular ATP-activated non-selective cation channel. Plays particularly important role in sensory neurons where its activation is critical for gustatory, nociceptive responses, visceral reflexes and sensory hypersensitization (By similarity). (UniProt, P56373)

Open in Phaseline: the race on P2RX3, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
GSKCamlipixant (BLU-5937)
P2X purinoceptor 3 antagonist
P2RX3Phase 3Refractory Chronic Cough; Irritable Bowel SyndromeMar 2027
Bellus Health Inc. - a GSK companyCamlipixant (BLU-5937)
P2X purinoceptor 3 antagonist
P2RX3Phase 3CoughMar 2027

Conditions

Cough (1) Refractory Chronic Cough (1) Irritable Bowel Syndrome (1)

Modalities

small molecule (2)

Companies

Bellus Health Inc. - a GSK company (1) GSK (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.